UBS Downgrades Idenix Pharmaceuticals Inc. (IDIX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Achillion Pharmaceuticals (ACHN) Price Target Raised to $7-$8 at Wells Fargo
June 23, 2014 2:40 PM EDTWells Fargo maintained a Market Perform rating on Achillion Pharmaceuticals (NASDAQ: ACHN) and raised its price target to $7-$8 (from $2.50-$3.50). Analyst Brian Abrahams made note of the high value being placed on nucs by large pharma and competitive bidding for peer Idenix... More
